Heart1.com: Great Information, Real Community, Better Living.
 Main Page
 Heart News
Feature Story
 Education Center
 Heart Attack Center
Dr. Tod Engelhardt  Heart

Dr. Tod Engelhardt:
Combating Major Blood Clots.
About Heroes
 Join the Discussion  in  Our Forums
Heart1 Forums
Patient Stories
Online Resources
Video Library
Search the Body1 Network
May 22, 2019  
HEART NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Links/Reprints
  • At-Home Device Would Check Blood Thinning

    At-Home Device Would Check Blood Thinning

    March 08, 2004

    PHILADELPHIA (AP) - Three university scientists are developing a prototype device that they say will allow patients on blood thinning medication to take their own blood-clotting readings at home.

    The cell phone-sized device would work like the machines that diabetics use to check their blood glucose levels, according to the Drexel University researchers, who recently founded a firm called BioSensus to develop and market the NanoAcoustic Blood Analyzer.

    "Patients become more confident and in control of their own fate by taking their own readings," said J. Yasha Kresh, a professor at Drexel's College of Medicine.

    The researchers said that their device is different from other blood analyzers on the market because it can be targeted to read the amounts of specific kinds of proteins in the blood that are involved in clotting and bleeding.

    Other blood-testing machines on the market use a system of capillary-sized tubes to determine blood's thickness by measuring how quickly it works its way through the tiny mazelike structure. The Drexel scientists say their nearly submicroscopic technology - analyzing particles 1/75th the width of a human hair - would more easily adapt to a wide variety of uses other than blood thickness and to adjust for as-yet undiscovered medicines.

    "We're very excited about this technology and the improvement of quality of life than it can bring," said professor Ryszard M. Lec of Drexel's School of Biomedical Engineering.

    Such technology, if and when it happens, could empower patients by giving them a bigger role and could help doctors provide better care, said Dr. Richard C. Becker, an American Heart Association spokesman and a professor at the Duke University School of Medicine. Though he stresses that it's too soon to say whether the Drexel project's promise, or any nanotechnology experiments in the works, will make the leap from trial to reality.

    "This technology hasn't reached that point, but there certainly is a great deal of interest in the scientific, medical and technology communities for it," Becker said.

    Blood thinners like warfarin, also known as Coumadin, can be time-consuming for doctors to prescribe, since they cannot easily figure out how much to give. Two people the same size, sex and age may require vastly different doses to achieve the same result. Doctors set the dose by regularly testing the drug's effect on patients' blood clotting.

    Warfarin is widely prescribed after strokes, heart valve replacement surgery, heart attacks and orthopedic surgery. It is also given to prevent recurring clots in the legs or lungs. However, dosing can be touchy: Too little, and there's risk of clots; too much, and there's risk of internal bleeding.

    The prototype being worked on at Drexel, like blood glucose machines that diabetics use, works like this: A patient pricks their finger and puts a drop of blood on a testing strip. The strip is then placed inside the monitor and gives a reading.

    The technology used in the NanoAcoustic machine also could be adapted to "ask blood almost any type of question," Lec said. That means it also could potentially read blood in a way to test clotting levels of people with hemophilia, for example, or be developed to screen for specific proteins in +urine+ or saliva for markers that indicate other kinds of ailments, Lec said.

    The researchers estimate that the machine will cost about $150 to $200 and the testing strips around $3 a piece.

    BioSensus received a $500,000 startup grant from BioAdvance, the biotechnology greenhouse of Southeastern Pennsylvania, to produce the laboratory prototype. The researchers expect a commercial prototype to be completed within the next 18 months and ready for use and feedback from doctors' offices and emergency rooms.


    On the Net:

    Drexel University: http://www.drexel.edu

    Last updated: 08-Mar-04


  • Add Comment
    Interact on Heart1

    Discuss this topic with others.
    Feature Archives

    Heart Disease Patients Need to Exercise to Benefit from the Protective Effects of Wine

    Effective Treatment for Heart Failure Possible Following Discovery of Heart Molecule

    Significant Decrease in Heart Disease after Prison Smoking Bans

    Heart Failure Patients Who Sleep Poorly Are at Double the Risk for Hospitalization

    Long-Term Survival Possible for Pediatric Heart Transplant Patients

    Next 5 Features ...

    More Features ...
    Related Multimedia

    Cholesterol and the Ejection Fraction: Risk factors for Cardiac Arrests - Interview with Dr. Coman

    Patients who have Pacemakers and need MRI Scans - Interview with Dr. Coman

    Interview with Dr. Patel: Future of Arthroscopy

    More Features ...
    Related Content
    Heart-Healthy Eating For People With Diabetes

    New Device Lowers Heart Attack Risk

    Babies Can Get Hearts With Wrong Blood

    Meditation Impacts Teen Blood Pressure

    Study Questions Value of Inflammation Test

    More Features ...
    Home About Us Press Jobs Advertise With Us Contact Us
    © 2019 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.